+

WO1991018610A1 - New use of glucose and a new solution of glucose - Google Patents

New use of glucose and a new solution of glucose Download PDF

Info

Publication number
WO1991018610A1
WO1991018610A1 PCT/SE1991/000376 SE9100376W WO9118610A1 WO 1991018610 A1 WO1991018610 A1 WO 1991018610A1 SE 9100376 W SE9100376 W SE 9100376W WO 9118610 A1 WO9118610 A1 WO 9118610A1
Authority
WO
WIPO (PCT)
Prior art keywords
glucose
glutamine
infusion solution
patient
fructose
Prior art date
Application number
PCT/SE1991/000376
Other languages
French (fr)
Inventor
Olle Ljungqvist
Original Assignee
Olle Ljungqvist Medical Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Olle Ljungqvist Medical Ab filed Critical Olle Ljungqvist Medical Ab
Publication of WO1991018610A1 publication Critical patent/WO1991018610A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0029—Parenteral nutrition; Parenteral nutrition compositions as drug carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins

Definitions

  • the present invention relates to a new use of glucose, fruc ⁇ tose and/or xylose and an infusion solution intended for preoperative administration.
  • the invention also relates to a method of suppressing the negative influence on the metabolism of carbohydrates caused by surgery and improv ⁇ ing the defence capacity of the patient upon bleeding during or after the operation.
  • Elective surgical (i.e. not acute) operations are yearly carried out at a number of approximately 2-300000 in Sweden alone.
  • a routine operation always brings about a relative ⁇ ly long period (weeks) of convalescence for physical re- covery.
  • Routinely all patients planned for surgery undergo a period of fasting before the operation, usually from mid ⁇ night to the day of surgery.
  • the effective period of fast ⁇ ing becomes at least 16-20 h because the last meal of food generally is served around 16.00 h.
  • the obli- gatory fast before surgery has been introduced for reasons of safety related to anaesthesia and has not been consider ⁇ ed to bring about negative effects for the patient.
  • glutamine is supplied by means of the food intake, but during fasting (and to a greater extent after trauma) the glutamine requirements of the bowel is supplied via degradation of glutamine stored in the pro ⁇ teins &£ the muscles.
  • the release of hormones in the body must change. By changes in hormone release, the body thus changes from storage of nutrients (anabolism) to degradation of nutrients (catabolism) . This shift in body metabolism forms a normal part of metabolism and occurs already during normal overnight sleep.
  • specific hormones primarily insulin
  • the present invention is based on the finding that it was possible by preoperative administration of a solution con ⁇ taining glucose not only to improve the body's capacity of the patient to withstand blood loss during or after surgery but also to improve postoperative carbohydrate metabolism by reducing the degree of insulin resistance after the operation.
  • Glucose treated rats had 578 ⁇ dry liver weight (mean ⁇ SE) of glycogen compared to 104 ⁇ 32A/ mol/g, significance p ⁇ 0.01 (Mann Whitney U-test) .
  • G had blood glucose levels of 16.1 ⁇ 0.9 mmol/1 compared to S 5.2 ⁇ 0.1, p ⁇ 0.01.
  • This increase in blood glucose in group G resulted in improved fluid mobilization to the circula ⁇ tion, as indicated by a lower haematocrit in group G (35 ⁇ 1 %) versus group S (40 ⁇ 1 %) , p ⁇ 0.01.
  • Rats pretreated with glucose showed a hor ⁇ mone response with increased insulin levels in the blood in a way which previously has been observed only in not fasted animals and subjected to haemorrhage. This insulin release is not found in 24 h fasted (and untreated) rats, nor could it be reproduced by treatment initiated once the bleeding had been started. 2. Clinical experiments.
  • the present invention relates to the use of at least one carbohydrate selected from •the-group consisting of glucose, fructose and zylose, preferably glucose, for the preparation of an infusion solution intended for preoperative administration in or- - der to suppress the negative influence of the operation -upon postoperative carbohydrate metabolism and to improve the defence capacity of the patient in case of bleeding in connection with or after the operation without anaeste- siological safety being jeopardized.
  • carbohydrate selected from •the-group consisting of glucose, fructose and zylose, preferably glucose
  • the content of qlucose etc. in the infusion solution is suit ⁇ ably within the range which usually is used in nutrient solutions for intravenous supply of nutrients to patients which can not support themselves after surgery, for in ⁇ stance within the range from 50 g/1 to 500 g/1, prefer ⁇ ably 100 g/1 to 200 g/1.
  • the infusion solution in addition to the glucose also contains potassium chloride.
  • the content is also in this case suit ⁇ ably within the range which is usually occurring in solutions for nutrient supply after surgery.
  • the content of potasium chloride may be in the rang from 20 mmol/1 to 100 mmol/1, preferably about 40 rnmol/1.
  • the in ⁇ fusion solution may in addition ' to glucose and possibly potassium chloride also contain at least one of the sub ⁇ stances fructose and xylose.
  • the content of fructose or xylose or mixture thereof is suitably within the range from 50 g/1 to 200 g/1, preferably 50 g/1 to 100 g/1.
  • the in ⁇ fusion solution may in addition to glucose and possibly potassium chloride and/or fructose and/or xylose also contain glutamine and/or ornii ⁇ ine-alfa-ketoglutarate or corresponding glur tamine analogues which in the body are converted to glutamine.
  • the body reserves of glutamine in the body are increased instead of decreased during the period of preoperative fasting.
  • This improvement of availability of body gluta ⁇ mine will reduce the need for muscle protein breakdown for the release of glutamine, which is otherwise en ⁇ countered after surgery. This, in turn, can improve post ⁇ operative muscle function.
  • the content of glutamine etc. is suitably within the range 5 g/1 to 30 g/1, preferably 10 g/1 to 20 g/1.
  • the infusion solution may in addition to glucose and possibly potassium chloride and possibly one or more of the pre ⁇ viously mentioned additional substances also contain.c ⁇ ie or more hormones such as an insulin or insulin derivative which is suitable for administration to man.
  • the content is adjusted so that a suitable dose of insulin is given with the infused amount of solution.
  • suitable insulins and insulin derivatives in this connection is human insulin such as Humilin NPH (Lilly) or A ⁇ trapid ⁇ Human (Novo) .
  • insulin is the most important hormone for the normal storage off nutrients, other hormones and peptides also have anabolic effects on body metabolism.
  • growth hormone, insulin growth factor as well as GLIP have been suggested to have insulin like effects.
  • the infusion solu ⁇ tion may also contain other substances which are occurring in nutrient solutions for intravenous administration, if desired.
  • the infusion solution is drawn into glass bottles or plas ⁇ tics bags of 500 ml - 2000 ml.
  • the patient is given glucose 3-5 mg/kg/min intravenously (corresponding to about 60-100 ml/h 20 mg/ml glucose solution to a pa ⁇ tient weighing 70 kg) .
  • the solutions can be packed up in different sizes in order to correspond to the need of pa ⁇ tients of different weights.
  • this is rela ⁇ ted to an infusion solution, which is characterized in that it in addition to at least one carbohydrate select ⁇ ed from the group consisting of glucose, fructose and xylose, preferably glucose, and potassium chloride also contains ornitnine-alfa-ketoglutarate and/or glutamine and possibly one or more hormones.
  • carbohydrate select ⁇ ed from the group consisting of glucose, fructose and xylose, preferably glucose, and potassium chloride also contains ornitnine-alfa-ketoglutarate and/or glutamine and possibly one or more hormones.
  • this is related to a method f ⁇ tTsuppressing the negative influ ⁇ ence upon the metabolism of carbohydrates caused by an operation of a patient and improving the defence capacity of the patient on bleeding in connection with or after the operation which method comprises preoperative intra ⁇ venous administration of the patient of an infusion solu ⁇ tion containing at least one carbohydrate selected from the group consisting of glucose, fructose and xylose, preferably glucose.
  • infusion solution is prepared in a conventional way for the preparation of infusion solutions, which infusion solution contains glucose (200 mg/ml) and potassium chloride (40 mmol/1) and the solution is d__awn-.iit.tovolumes of 1500 ml.
  • An infusion solution is prepared in a way conventional to the preparation of infusion solutions, which solution con ⁇ tains glucose (200 mg/ml) , potassium chloride (40 mmol/1) and human insulin (Actrapicr ⁇ Human, Novo, Denmark, 20 IE/1) and the solution is drawn into volumes of 1300 ml.
  • An infusion solution is prepared in a way conventional to the preparation of infusion solutions, which solution con- tains glucose (150 mg/ml) , fructose (50 mg/ml) and potas ⁇ sium chloride (40 mmol/1) , and the solution is drawn into volumes of 1200 ml.
  • An infusion solution is prepared in a way conventional to the preparation of infusion solutions, which solution con ⁇ tains glucose (200 mg/ml) , orn__thine- : a-_fa-ketoglutarate (10 mg/ml) and potassium chloride (40 mmol/1) , and the solu- tion is drawn into volumes of 1500 ml.
  • the best mode for carrying out the invention at present comprises the preoperative administration of an infusion solution comprising glucose and potassium chloride dissolv ⁇ ing water.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Inorganic Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

Glucose, fructose and/or xylose are suggested to be used for the preparation of an infusion solution intended for preoperative administration. An infusion solution is disclosed, which in addition to glucose, fructose and/or xylose and potassium chloride also contains glutamine and/or ornithine-alfa-ketoglutarate or the corresponding glutamine analogues which are transformed into glutamine in the body and possibly one or more hormones. Furthermore, a method is disclosed for suppressing the negative influence of an operation on patient carbohydrate metabolism after surgery and improving the defence capacity of the patient on bleeding in connection with or after the operation which method comprises preoperative intravenous administration to the patient of an infusion solution containing at least one carbohydrate selected from the group consisting of glucose, fructose and xylose.

Description

NEW USE OF GLUCOSE AND A NEW SOLUTION OF GLUCOSE
The present invention relates to a new use of glucose, fruc¬ tose and/or xylose and an infusion solution intended for preoperative administration. The invention also relates to a method of suppressing the negative influence on the metabolism of carbohydrates caused by surgery and improv¬ ing the defence capacity of the patient upon bleeding during or after the operation.
Elective surgical (i.e. not acute) operations are yearly carried out at a number of approximately 2-300000 in Sweden alone. A routine operation always brings about a relative¬ ly long period (weeks) of convalescence for physical re- covery. Routinely all patients planned for surgery undergo a period of fasting before the operation, usually from mid¬ night to the day of surgery. The effective period of fast¬ ing, however, becomes at least 16-20 h because the last meal of food generally is served around 16.00 h. The obli- gatory fast before surgery has been introduced for reasons of safety related to anaesthesia and has not been consider¬ ed to bring about negative effects for the patient.
However, a considerable change in body metabolism occurs already during the period of preoperative fasting. Most important is the fact that the reserves of carbohydrates in the body (primarily glycogen in the liver) are consumed. The requirements of the brain of glucose, however, remains unchanged for some additional days. To meet this demand for glucose, the body metabolism is changed, so that new glu¬ cose can be produced. Glucose production is accomplished by degradation of glucose and fat reserves (in muscle and fat tissue) , and by degradation of protein in muscle. There¬ by, amino acids (alanine and glutamine and others) are re- leased and transported to the liver for new glucose forma¬ tion. Of particular interest is that the bowel for its meta- bolism, to a large extent is dependent on the amino acid glutamine. Normally, glutamine is supplied by means of the food intake, but during fasting (and to a greater extent after trauma) the glutamine requirements of the bowel is supplied via degradation of glutamine stored in the pro¬ teins &£ the muscles. In order to enable the degradation of the energy depots of the body to take place, the release of hormones in the body must change. By changes in hormone release, the body thus changes from storage of nutrients (anabolism) to degradation of nutrients (catabolism) . This shift in body metabolism forms a normal part of metabolism and occurs already during normal overnight sleep. When the first meal of the day is ingested, the body responds by activating specific hormones (primarily insulin) to ensure the storage of the received energy of carbohydrates, pro¬ tein and fat.
Thus already preoperative fasting leads to two essential changes in the metabolism of carbohydrates: 1. consumption of glucose reserves, and 2. changes in metabolism
These changes in the metabolism of carbohydrates in the body has important consequences for the immediate response to stress, as well as for the recovery after stress and sur¬ gery.
It has been documented that a reduction of the carbohydrate reserves (glycogen) in the liver, which occurs already af- ter a brief period of fasting (6-24 hours in the rat and man) , brings about increased mortality in experimental haemorrhage and endotoxaemia. In experiments of haemorrh¬ age in rats, it has been proven that the glycogen of the liver is rapidly mobilized (as glucose) to the blood circu- lation, where markedly increased glucose levels could be registered. The increase in blood glucose thus obtained. actively participates- in the blood volume preservation by mobilizing fluid by osmosis from the large fluid re¬ serve located within the body cells to the circulation. Already after a short period of fasting (hours), this po- 5 tential for fluid mobilization is decreased. This mecha¬ nism for fluid defense exists in the majority of mammals, including man. The preoperative fast accordingly causes a considerable reduction in the potential to maintain adequate circulation (e.g. blood volume) in case of 10. bledding during or after surgery.
In all types of stress (including surgery) body metabolism is rapidly changed into a state, where the normal balance between catabolic and anabolic processes is strongly dis-
15 placed towards catabolism. The most important factor known for this change to develope is a major reduction of the effects of insulin (which is the most important hormone known for storage of nutrients) . This condition is often called stress-induced insulin resistance. It has 0 been proven that the degree of insulin resistance develop¬ ing after elective surgery is increased with the magnitude of surgery (i.e. small operations result in lesser de¬ grees of insulin resistance compared to greater surgery) . Furthermore, the insulin resistance after surgery per- 5 sists for a long period of time and a normalization is found after approximately three weeks. As long as insu¬ lin resistance remains, the body has difficulties in re¬ covering. Therefore, it is desirable to reduce the magni¬ tude of insulin resistance after surgery as well as re- 0 storing the sensitivity of insulin as soon as possible. Essential for this recovery is a return to normal meta¬ bolism of carbohydrates. The brain, blood cells and other cells are completely dependent on carbohydrates (e.g. glucose) for their metabolism, whereas muscle require a 5 certain minimum of supply of carbohydrates for their func¬ tion. A simple way of reducing the degree of insulin re- sistance after surgery, and thus improving postoperative carbohydrate metabolism, has not been described in lite¬ rature.
The present invention is based on the finding that it was possible by preoperative administration of a solution con¬ taining glucose not only to improve the body's capacity of the patient to withstand blood loss during or after surgery but also to improve postoperative carbohydrate metabolism by reducing the degree of insulin resistance after the operation.
As far as it is known to-day, there has been no litera¬ ture that has been able to prove these effects by preope- rative supply of solutions containing glucose. The effect of preoperative administration of glucose on postopera¬ tive metabolism has been studied only in one previous ' investigation (Crowe et al., British J. Surg. 1984. 71; 635-637) . The investigation was specifically directed to postoperative metabolism of proteins, by measuring the excretion of urea and 3-methylhistidine/creatinine index in the urine. However, the investigation has serious scientific defects. The investigation was not randomized, and it is not evident what operations were performed in the different groups of patients. In view of the fact that the magnitude of surgery is directly decisive for the res¬ ponses of the body, it must be considered very difficult to draw any conclusions from this investigation. The authors own conclusion was that preoperative glucose supply possibly could be of use for postoperative meta¬ bolism of proteins, but there is no suggestion whatsoever that this pretreatment could bing about favourable effects for the metabolism of-carbohydrates, nor that such treat¬ ment could decrease the risks in case of bleeding compli- eating surgery. More particularly, the present invention is based on the following findings:
1. Experiments on animals.
Survival after 42 % blood loss in rats fasted for 24 h was compared after treatment with either 30 mg/ml glucose, 0.3 ml/kg body weight/h, intravenously, or after the same volume of 0.9 % NaCl given during 3 h before the start of haemorrhage. Ten animals were ^included in each of the treatment groups, glucose (G) or saline (S) , and sub¬ jected to 60 min of haemorrhage. Twelve additional ani¬ mals (6 G and 6 S) were sacrificed after infusion for de¬ termination of liver glycogen content. Glucose treated rats had 578 ±
Figure imgf000007_0001
dry liver weight (mean ± SE) of glycogen compared to 104 ± 32A/ mol/g, significance p < 0.01 (Mann Whitney U-test) . After haemorrhage, G had blood glucose levels of 16.1 ± 0.9 mmol/1 compared to S 5.2 ± 0.1, p <0.01. This increase in blood glucose in group G" resulted in improved fluid mobilization to the circula¬ tion, as indicated by a lower haematocrit in group G (35 ± 1 %) versus group S (40 ± 1 %) , p <0.01. While all animals pretreated with saline had died within 4 h after completion of haemorrhage, all animals given glucose prior to haemorrhage recovered completely after haemorr¬ hage (7 days of observation) .
The hormonal response on bleeding was investigated in two groups of rats pretreated according to the protocol de- scribed above. Rats pretreated with glucose showed a hor¬ mone response with increased insulin levels in the blood in a way which previously has been observed only in not fasted animals and subjected to haemorrhage. This insulin release is not found in 24 h fasted (and untreated) rats, nor could it be reproduced by treatment initiated once the bleeding had been started. 2. Clinical experiments.
In 12 patients, healthy apart from gallstone and operated electively for cholecystec omy, were randomly allocated into receiving either glucose 5 mg/kg/min intravenously from 6.00 pm the day before operation until start of sur¬ gery, or no infusion during this period (e.g. routine fasting period) . Insulin sensitivity (M- alue) was de¬ termined using the euglycemic hyperinsuline ic clamp tech- niques within 3 days prior to surgery, and on the first post-operative day. Pre-operative M- alues were similar in both groups (n = 6); 4.64 ± 1.36 mg/kg/min in glucose treated patients and 4.31 ± 0.35 mg/kg/min in fasted pa¬ tients, difference not significant. Postoperative M-value the day after surgery was significantly (p <0.02) lower in fasted patients (2.00 ± 0.21 mg/kg/min) compared to patients pretreated with glucose (3.14 ± 0.88 mg/kg/min). This finding shows that pretreatment with glucose infusion during preoperative fasting, significantly reduces the postoperative disturbance in carbohydrate metabolism.
Patients operated for gallstone desease have been pre¬ treated with either glucose in infusion (5 mg/kg/min) during preoperative fasting or traditional fasting before the same operation. Under operation small pieces of liver tissue have been taken for analysis of the content of glucose (glycogen) as well as of the activity of enzymes involved in the control of the metabolism of carbohydrates in the liver. Patients treated with glucose showed higher contents of glycogen at the same time as the enzymatic setting was adjusted in a way which is more associated with' that.seen after a meal (than the one seen after fasting) compared to patients which have fasted.
This difference in hepatic enzymatic adjustment has experi¬ mentally been shown to be associated with marked diffe- rences in post-stress metabolism. Enzymatic adjustment, such as that found after food intake was associated with improved post-stress carbohydrate metabolism.
In accordance with the above the present invention relates to the use of at least one carbohydrate selected from •the-group consisting of glucose, fructose and zylose, preferably glucose, for the preparation of an infusion solution intended for preoperative administration in or- - der to suppress the negative influence of the operation -upon postoperative carbohydrate metabolism and to improve the defence capacity of the patient in case of bleeding in connection with or after the operation without anaeste- siological safety being jeopardized.
The content of qlucose etc. in the infusion solution is suit¬ ably within the range which usually is used in nutrient solutions for intravenous supply of nutrients to patients which can not support themselves after surgery, for in¬ stance within the range from 50 g/1 to 500 g/1, prefer¬ ably 100 g/1 to 200 g/1.
According to a preferred embodiment of the invention the infusion solution in addition to the glucose also contains potassium chloride. The content is also in this case suit¬ ably within the range which is usually occurring in solutions for nutrient supply after surgery. For in¬ stance the content of potasium chloride may be in the rang from 20 mmol/1 to 100 mmol/1, preferably about 40 rnmol/1."
According to another embodiment of the invention the in¬ fusion solution may in addition'to glucose and possibly potassium chloride also contain at least one of the sub¬ stances fructose and xylose. The content of fructose or xylose or mixture thereof is suitably within the range from 50 g/1 to 200 g/1, preferably 50 g/1 to 100 g/1. According to a further embodiment of the invention the in¬ fusion solution may in addition to glucose and possibly potassium chloride and/or fructose and/or xylose also contain glutamine and/or ornii±ine-alfa-ketoglutarate or corresponding glur tamine analogues which in the body are converted to glutamine. By supplying glutamine and/or corresponding,glutamine analogues which in the body are converted to glutamine, the body reserves of glutamine in the body are increased instead of decreased during the period of preoperative fasting. This improvement of availability of body gluta¬ mine will reduce the need for muscle protein breakdown for the release of glutamine, which is otherwise en¬ countered after surgery. This, in turn, can improve post¬ operative muscle function. The content of glutamine etc. is suitably within the range 5 g/1 to 30 g/1, preferably 10 g/1 to 20 g/1.
According to still another embodiment of the invention the infusion solution may in addition to glucose and possibly potassium chloride and possibly one or more of the pre¬ viously mentioned additional substances also contain.cϋie or more hormones such as an insulin or insulin derivative which is suitable for administration to man. In this case the content is adjusted so that a suitable dose of insulin is given with the infused amount of solution.
Examples of suitable insulins and insulin derivatives in this connection is human insulin such as Humilin NPH (Lilly) or Aσtrapid~ Human (Novo) .
Although insulin is the most important hormone for the normal storage off nutrients, other hormones and peptides also have anabolic effects on body metabolism. Thus, growth hormone, insulin growth factor as well as GLIP have been suggested to have insulin like effects. By supplying one or more of these preopratively, the body metabolism is further adjusted to an anabolic state, which may prove beneficial for body reactions during and after surgery.
In addition to the mentioned additives the infusion solu¬ tion may also contain other substances which are occurring in nutrient solutions for intravenous administration, if desired.
The infusion solution is drawn into glass bottles or plas¬ tics bags of 500 ml - 2000 ml. During the period of fast before the operation, from about 18.00 the day before the operation to the start of operation, the patient is given glucose 3-5 mg/kg/min intravenously (corresponding to about 60-100 ml/h 20 mg/ml glucose solution to a pa¬ tient weighing 70 kg) . The solutions can be packed up in different sizes in order to correspond to the need of pa¬ tients of different weights.
According to another aspect of the invention this is rela¬ ted to an infusion solution, which is characterized in that it in addition to at least one carbohydrate select¬ ed from the group consisting of glucose, fructose and xylose, preferably glucose, and potassium chloride also contains ornitnine-alfa-ketoglutarate and/or glutamine and possibly one or more hormones. Such a solution for preoperative use has not been disclosed or suggested pre¬ viously as far as we know.
According to still another aspect of the invention this is related to a method fαtTsuppressing the negative influ¬ ence upon the metabolism of carbohydrates caused by an operation of a patient and improving the defence capacity of the patient on bleeding in connection with or after the operation which method comprises preoperative intra¬ venous administration of the patient of an infusion solu¬ tion containing at least one carbohydrate selected from the group consisting of glucose, fructose and xylose, preferably glucose.
The invention will be illustrated further in the following by means of a number of working examples to which however the invention should not be limited.
EXAMPLE 1
An infusion solution is prepared in a conventional way for the preparation of infusion solutions, which infusion solution contains glucose (200 mg/ml) and potassium chloride (40 mmol/1) and the solution is d__awn-.iit.tovolumes of 1500 ml.
In this way a package adjusted to a patient body weight of 70 kg is obtained which is to be administered during preoperative fastening to a patient which is healthy except the complain for which the patient is to be operated.
EXAMPLE 2.
An infusion solution is prepared in a way conventional to the preparation of infusion solutions, which solution con¬ tains glucose (200 mg/ml) , potassium chloride (40 mmol/1) and human insulin (Actrapicr^ Human, Novo, Denmark, 20 IE/1) and the solution is drawn into volumes of 1300 ml.
In this way a package adjusted to a patient bodyweight of 60.kg is obtained, which is to be administered during preoperative fastening to a patient with diabetes mellitus.
EXAMPLE 3.
An infusion solution is prepared in a way conventional to the preparation of infusion solutions, which solution con- tains glucose (150 mg/ml) , fructose (50 mg/ml) and potas¬ sium chloride (40 mmol/1) , and the solution is drawn into volumes of 1200 ml.
In this way a package adjusted to patient body weight is obtained, which is to be administered during preoperative fasting to a patient weighing about 50 kg.
EXAMPLE 4.
An infusion solution is prepared in a way conventional to the preparation of infusion solutions, which solution con¬ tains glucose (200 mg/ml) , orn__thine-:a-_fa-ketoglutarate (10 mg/ml) and potassium chloride (40 mmol/1) , and the solu- tion is drawn into volumes of 1500 ml.
In this way a package adjusted to patient body weight is obtained which is to be administered under preoperative fastening to a patient "having a weight of about 70 kg.
The best mode for carrying out the invention at present comprises the preoperative administration of an infusion solution comprising glucose and potassium chloride dissolv¬ ing water.

Claims

C L A I M S
1. The use of at least one carbohydrate selected from the group consisting of glucose, fructose and xylose, preferably glucose, for the preparation of an infusion solution intended for preoperative administration in or¬ der to suppress the negative influence of the operation upon the carbohydrate metabolism and to improve the de¬ fence capacity of the patient in case of bleeding in connection with or after the operation.
2. Use according to claim 1, characterized in that the infusion solution also contains potassium chloride.
3. Use according to claim 1 and/or 2, characterized in that the infusion solution in addition to glucose also contains at least one of the substances fructose and xylose.
4. Use according to one or more of claims 1 - 3, characterized in that the infusion solution also contains glutamine and/or .©rnithine-alfa-ketoglutarate or correspon ding glutamine analogues which are transformed into glu¬ tamine in the body.
5. Use according to one or more of claims 1 - 4, characterized in that the infusion solution also contains one or more hormones, preferably an insulin or insulin derivative suitable for administration to man.
6. Infusion solution for preoperative administration, characterized in that it consists of an aqueous solution of at least one carbohydrate selected from the group con¬ sisting of glucose, fructose and xylose, preferably glu- cose, and potassium chloride together with glutamine and/or ornithine-alfa-ketoglutarate or the corresponding glutamine analogues which are transformed into glutamine in the body and possibly one or more hormones.
7. Infusion solution according to claim 6, characterized in that the content of glutamine and/or ornithine-alfa- ketoglutarate or corresponding glutamine analogues which are transformed into glutamine in the body of the solu- 5 tion is 5-30 g/1, preferably 10-20 g/1.
# 8. Method for suppressing the negative influence of an operation on a patient carbohydrate metabolism after sur¬ gery and improving the defence capacity of the patient on
10 bleeding in connection with or after the operation, which ' method comprises preoperative intravenous administration to the patient of an infusion solution containing at least one carbohydrate selected from the group consisting of glucose, fructose and xylose, preferably glucose.
15
20
PCT/SE1991/000376 1990-05-28 1991-05-28 New use of glucose and a new solution of glucose WO1991018610A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9001906-8 1990-05-28
SE9001906A SE502414C2 (en) 1990-05-28 1990-05-28 Use of glucose for preparation of solution for preoperative administration and infusion solution therefore

Publications (1)

Publication Number Publication Date
WO1991018610A1 true WO1991018610A1 (en) 1991-12-12

Family

ID=20379607

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/SE1991/000376 WO1991018610A1 (en) 1990-05-28 1991-05-28 New use of glucose and a new solution of glucose

Country Status (3)

Country Link
AU (1) AU7957991A (en)
SE (1) SE502414C2 (en)
WO (1) WO1991018610A1 (en)

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992010947A1 (en) * 1990-12-21 1992-07-09 Olle Ljungqvist Medical Aktiebolag Beverage for preoperative intake
EP0875155A1 (en) * 1997-05-01 1998-11-04 N.V. Nutricia Peri-operative drink
US5968896A (en) * 1998-01-16 1999-10-19 Beth Israel Deaconess Medical Center Nutritional supplement for preoperative feeding
WO2001035943A3 (en) * 1999-11-15 2002-03-21 Hanamaraddi T Gangal Dextrose and insulin fluid formulation for intravenous infusion
US6475529B2 (en) 1999-09-10 2002-11-05 Baxter International Inc. Bicarbonate-based solution in two parts for peritoneal dialysis or substitution in continuous renal replacement therapy
EP1380290A1 (en) * 2002-07-09 2004-01-14 Universitair Medisch Centrum Utrecht Cross-beta structure pathway and its therapeutic relevance
WO2004052352A1 (en) * 2002-12-09 2004-06-24 Fresenius Kabi Deutschland Gmbh Formulation, which can be administered gastrointestinally, containing green tea extract and an no donor
EP1591116A1 (en) * 2003-02-06 2005-11-02 Otsuka Pharmaceutical Factory, Inc. Inhibitor for perioperative blood sugar elevation
US7011855B2 (en) 1994-07-01 2006-03-14 Baxter International Inc. Biochemically balanced peritoneal dialysis solutions
US7122210B2 (en) 2002-01-11 2006-10-17 Baxter International Inc. Bicarbonate-based solutions for dialysis therapies
US7445801B2 (en) 2002-06-07 2008-11-04 Baxter International Inc. Stable bicarbonate-based solution in a single container
EP2033623A1 (en) * 2007-09-07 2009-03-11 Cutech S.R.L. Compositions comprising ornithine ketoglutarate (OKG)
WO2011069932A1 (en) * 2009-12-10 2011-06-16 Chiesi Farmaceutici S.P.A. Novel therapeutic uses for an ornithine alpha-ketoglutarate complex
US9180069B2 (en) 2005-01-28 2015-11-10 Fresenius Medical Care Holdings, Inc. Systems and methods for delivery of peritoneal dialysis (PD) solutions
US9585810B2 (en) 2010-10-14 2017-03-07 Fresenius Medical Care Holdings, Inc. Systems and methods for delivery of peritoneal dialysis (PD) solutions with integrated inter-chamber diffuser

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
PATENT ABSTRACTS OF JAPAN, Vol. 10, No. 182, C356; & JP,A,61 030 523, 12-02-1986, TERUMO CORP. *
PATENT ABSTRACTS OF JAPAN, Vol. 10, No. 252, C369; & JP,A,61 078 719, 22-04-1986, TANABE SEIYAKU CO LTD. *

Cited By (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5438043A (en) * 1990-12-21 1995-08-01 Olle Ljungqvist Medical Ab Beverage for preoperative intake
US5624907A (en) * 1990-12-21 1997-04-29 Olle Ljungqvist Medical Ab Beverage for preoperative intake
WO1992010947A1 (en) * 1990-12-21 1992-07-09 Olle Ljungqvist Medical Aktiebolag Beverage for preoperative intake
US7011855B2 (en) 1994-07-01 2006-03-14 Baxter International Inc. Biochemically balanced peritoneal dialysis solutions
EP0875155A1 (en) * 1997-05-01 1998-11-04 N.V. Nutricia Peri-operative drink
WO1998049906A1 (en) * 1997-05-01 1998-11-12 N.V. Nutricia Peri-operative drink
US5968896A (en) * 1998-01-16 1999-10-19 Beth Israel Deaconess Medical Center Nutritional supplement for preoperative feeding
US6475529B2 (en) 1999-09-10 2002-11-05 Baxter International Inc. Bicarbonate-based solution in two parts for peritoneal dialysis or substitution in continuous renal replacement therapy
RU2300367C2 (en) * 1999-11-15 2007-06-10 Ханамарадди Т. ГАНГАЛ Liquid curative composition containing dextrose and insulin for intravenous administration
WO2001035943A3 (en) * 1999-11-15 2002-03-21 Hanamaraddi T Gangal Dextrose and insulin fluid formulation for intravenous infusion
US7122210B2 (en) 2002-01-11 2006-10-17 Baxter International Inc. Bicarbonate-based solutions for dialysis therapies
US7445801B2 (en) 2002-06-07 2008-11-04 Baxter International Inc. Stable bicarbonate-based solution in a single container
AU2003251233B2 (en) * 2002-07-09 2009-10-29 Crossbeta Biosciences B.V. Proteins binding to cross-beta structure comprising amyloid and methods for detection and modulation of the cross-beta structure, its formation and its associated toxicity
WO2004004698A3 (en) * 2002-07-09 2004-06-10 Univ Medisch Centrum Utrecht Proteins binding to cross-beta structure comprising amyloid and methods for detection and modulation of the cross-beta structure, its formation and its associated toxicity
EP1380290A1 (en) * 2002-07-09 2004-01-14 Universitair Medisch Centrum Utrecht Cross-beta structure pathway and its therapeutic relevance
HRP20050511B1 (en) * 2002-12-09 2008-01-31 Fresenius Kabi Deutschland Gmbh Formulation, which can be administered gastrointestinally, containing green tea extract and an no donor
WO2004052352A1 (en) * 2002-12-09 2004-06-24 Fresenius Kabi Deutschland Gmbh Formulation, which can be administered gastrointestinally, containing green tea extract and an no donor
KR101031989B1 (en) * 2002-12-09 2011-05-02 프레제니우스 카비 도이치란트 게엠베하 Formulations administrable to the gastrointestinal tract containing green tea extract and NO donor
EP1591116A4 (en) * 2003-02-06 2008-05-28 Otsuka Pharma Co Ltd INHIBITOR OF INCREASE IN PERIOPERATIVE GLYCEMIC RATE
US8273717B2 (en) 2003-02-06 2012-09-25 Otsuka Pharmaceutical Factory, Inc. Inhibitor for perioperative blood sugar elevation
EP1591116A1 (en) * 2003-02-06 2005-11-02 Otsuka Pharmaceutical Factory, Inc. Inhibitor for perioperative blood sugar elevation
US9180069B2 (en) 2005-01-28 2015-11-10 Fresenius Medical Care Holdings, Inc. Systems and methods for delivery of peritoneal dialysis (PD) solutions
WO2009030453A1 (en) * 2007-09-07 2009-03-12 Cutech Srl. Compositions comprising ornithine ketoglutarate (okg)
JP2011514878A (en) * 2007-09-07 2011-05-12 キューテック・ソシエタ・ア・レスポンサビリタ・リミタータ Ornithine ketoglutarate (OKG) -containing composition
US8466112B2 (en) 2007-09-07 2013-06-18 Cutech S.R.L. Compositions comprising Ornithine Ketoglutarate (OKG)
EP2033623A1 (en) * 2007-09-07 2009-03-11 Cutech S.R.L. Compositions comprising ornithine ketoglutarate (OKG)
WO2011069932A1 (en) * 2009-12-10 2011-06-16 Chiesi Farmaceutici S.P.A. Novel therapeutic uses for an ornithine alpha-ketoglutarate complex
FR2953719A1 (en) * 2009-12-10 2011-06-17 Luc Cynober NEW THERAPEUTIC APPLICATIONS OF A COMPLEX OF ALPHA-KETOGLUTARATE AND ORNITHINE
US9585810B2 (en) 2010-10-14 2017-03-07 Fresenius Medical Care Holdings, Inc. Systems and methods for delivery of peritoneal dialysis (PD) solutions with integrated inter-chamber diffuser
US10842714B2 (en) 2010-10-14 2020-11-24 Fresenius Medical Care Holdings, Inc. Systems and methods for delivery of peritoneal dialysis (PD) solutions with integrated inter chamber diffuser
US11779519B2 (en) 2010-10-14 2023-10-10 Fresenius Medical Care Holdings, Inc. Systems and methods for delivery of peritoneal dialysis (PD) solutions with integrated inter-chamber diffuser

Also Published As

Publication number Publication date
SE502414C2 (en) 1995-10-16
SE9001906D0 (en) 1990-05-28
AU7957991A (en) 1991-12-31
SE9001906L (en) 1991-11-29

Similar Documents

Publication Publication Date Title
Epstein Mineralocorticoids and cerebral angiotensin may act together to produce sodium appetite
WO1991018610A1 (en) New use of glucose and a new solution of glucose
KoNTUREK et al. Effect of growth hormone-release inhibiting hormone on hormones stimulating exocrine pancreatic secretion.
Clemmons et al. Reversal of diet-induced catabolism by infusion of recombinant insulin-like growth factor-I in humans
Bratusch-Marrain et al. Efficacy of pulsatile versus continuous insulin administration on hepatic glucose production and glucose utilization in type I diabetic humans
CA1336815C (en) Method for preventing secondary effects
Clemmons et al. Role of insulin-like growth factors and growth hormone in reversing catabolic states
EP0564511B1 (en) Beverage for preoperative intake
Gibson et al. Growth hormone and insulin-like growth factors in critical illness
Wolf et al. Growth hormone and IGF-I therapy in the hypercatabolic patient
CA2218018A1 (en) Method of administration of igf-i
Koea et al. Anabolic and cardiovascular effects of recombinant human growth hormone in surgical patients with sepsis
Michelsen et al. Effect of an anabolic steroid on nitrogen balance and amino acid patterns after total hip replacement
US4863901A (en) Use of growth hormone for nitrogen retention under hypocaloric conditions
Jeevanandam et al. Integrated nutritional, hormonal, and metabolic effects of recombinant human growth hormone (rhGH) supplementation in trauma patients
Vazquez et al. Protective effect of enriched diet plus growth hormone administration on radiation-induced intestinal injury and on its evolutionary pattern in the rat
Koea et al. Synergistic effect of insulin-like growth factor-I administration on the protein-sparing effects of total parenteral nutrition in fasted lambs
Panel Consensus statement: benefits versus risks of medical therapy for acromegaly
US6153581A (en) Drug for recovering renal function
Smedh et al. Fourth ventricle injection of corticotropin-releasing factor and gastric emptying of glucose during gastric fill
Shirabe et al. Resistance to ischemic conduction block of the peripheral nerve in hyperglycemic rats: an electrophysiological study
AU2004211961B2 (en) Method for treating hypothyroidism
AU650050B2 (en) Product and use of it for the treatment of catabolic states comprising authentic IGF-1 and hypocaloric amount of nutritients
Tikiz et al. The effect of vasoactive intestinal peptide (VIP) and naloxone combination on survival rates in rats exposed to severe hemorrhage
Van Hoorn et al. The metabolic clearance of endogenous immunoreactive glucagon and exogenous glucagon in pancreatectomized and sham-operated pigs

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA FI JP NO US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LU NL SE

NENP Non-entry into the national phase

Ref country code: CA

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载